Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Beta-blockers in chronic heart failure].

Jolanta Petruk-Kowalczyk1

  • 1Klinika Kardiologii 4 Wojskowego Szpitala Klinicznego we Wrocławiu.

Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|July 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Effect of sildenafil on haemodynamic parameters of pulmonary circulation and physical capacity in patients with systolic chronic heart failure with secondary severe pulmonary hypertension].

Kardiologia polska·2011
Same author

[Clinical significance and prognostic value of anemia in heart failure patients].

Kardiologia polska·2007
Same author

Persistent high NTpro-BNP concentration as a negative prognostic factor in patients with decompensated heart failure.

Kardiologia polska·2006
Same author

[Clinical use of ventilation measurement during early phase of exercise in patients with chronic heart failure].

Polskie Archiwum Medycyny Wewnetrznej·2004

Beta-blockers are crucial for treating chronic heart failure (CHF), alongside ACE inhibitors, based on updated understanding of CHF pathogenesis and clinical trial data. Further research is needed to fully resolve remaining questions regarding their optimal use in CHF patients.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Chronic heart failure (CHF) is a growing global health concern with a poor prognosis.
  • The role of beta-blockers in CHF management has evolved significantly over two decades.
  • Sympathetic nervous system and renin-angiotensin-aldosterone system activation are implicated in CHF pathogenesis.

Purpose:

  • To review the current understanding of CHF pathogenesis.
  • To elucidate the mechanisms behind the beneficial effects of beta-blockers in CHF.
  • To analyze clinical trial data on beta-blocker efficacy across different CHF stages and patient populations.

Summary:

  • Beta-blockers, alongside ACE inhibitors, are foundational treatments for CHF as per major cardiology guidelines.
  • Clinical evidence supports the effectiveness of beta-blockers in various CHF stages, including in elderly patients.

Related Experiment Videos

  • Despite increasing use, some aspects of beta-blocker therapy in CHF require further investigation and clarification.

    • Impact:

    • Provides a comprehensive overview of beta-blocker therapy in chronic heart failure.
    • Highlights the established and evolving role of beta-blockers in current CHF treatment guidelines.
    • Identifies areas for future research to optimize beta-blocker utilization in managing heart failure.